This application relates to the selection, Isolation and purification of Proteins that belong to own or vnar called vhnar variable regions of immunoglobulin receptor IgNAR type antigens and from elasmobranchs, the Clones from which they derive Vegfvnar called v32r and V19, and the respective Antibodies are called v32r and V19.Their sequences aminoac\u00eddicas were Elucidated, as well as their Tertiary Structures, and determined its ability to Neutralize the activity of vascular endothelial growth factor (VEGF). During the development of the application of these Proteins were optimized for expression in a production model of E. coli at industrial level.The application involves the use of these Antibodies in general to treat conditions related to angiogenesis or neovascularization and particularly to treat conditions related ocular neovascularisation by topical Administration.Claim 1: a vnar anti VEGF protein isolated and selected from the group consisting of V19 and v32r which comprises the Amino Acid Sequence seq. Or SEQ ID no. 4. Id. no. 6 and has Recognition ability and enhanced Affinity for its target Molecule VEGF.La presente solicitud se refiere a la selección, aislamiento y purificación de proteínas que pertenecen a regiones variables denominadas VHNAR ó vNAR propias de las inmunoglobulinas tipo IgNARs receptoras de antígenos y que provienen de elasmobranquios las clonas de las cuales derivan se les denomina VEGFvNAR V32R y V19, y a los anticuerpos respectivos se les denomina V32R y V19. Sus secuencias aminoacídicas fueron elucidadas, así como sus estructuras terciarias, y se determinó su capacidad para neutralizar la actividad del factor de crecimiento vascular endotelial (VEGF). Durante el desarrollo de la solicitud estas proteínas fueron optimizadas para expresarse en un modelo de producción de E. coli a nivel industrial. La solicitud implica el uso de estos anticuerpos en general para tratar padecimientos relacionados con la angiogénesis o neovascularizac
